// App-Quantinova.ai

4009 : Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity.

Researchers

Presenter

  • Hyun Cheol Chung

Principal Investigators

  • Lucjan Wyrwicz

  • Do-Youn Oh

  • Keun-Wook Lee

  • Jeffrey R. Infante

  • Sung Sook Lee

  • Jeeyun Lee

  • Ulrich Keilholz

  • Alain C. Mita

  • Elizabeth R. Plummer

  • Margaret Kemeny

  • Bohuslav Melichar

  • Denis Michel Smith

  • Kevin M. Chin

  • Anja von Heydebreck

  • Jean-Marie Cuillerot

  • Yoon-Koo Kang

  • Howard Safran

Medical Centers

  • Sarah Cannon Research Institute UK, London and University College London Hospitals., London, United Kingdom

  • Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland

  • Sarah Cannon Research Institute, Nashville, TN

  • Department for Hemato-Oncology, Comprehensive Cancer Center, Charite-University Medicine, Berlin, Germany

  • Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai, Los Angeles, CA

  • Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom

  • Queens Cancer Center of Queens Hospital, Jamaica, NY

  • Palacky University Medical School & Teaching Hospital, Olomouc, Czech Republic

  • Hopital Saint-Andre, Bordeaux, France

  • EMD Serono, Inc, Billerica, MA

  • Merck KGaA, Darmstadt, Germany

  • EMD Serono, Inc, Billerica, MA

  • Brown University Urology, Providence, RI

Locations

  • Czech Republic

  • Poland

  • Germany

  • United Kingdom

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastroesophageal junction (GEJ) adenocarcinoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Avelumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01772004

  • NCT017720042

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved